SEFA

NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Pediatrics, Hope, PRV, SEFA, PK, Priority review, Pharmacotherapy, Hospital, Nutritional science, RPD, Fatty liver disease, NASH, Gastrointestinal tract, NST, NDA, Parent, PD, DSM-IV codes, Parenteral nutrition, TPN, Short bowel syndrome, Portsmouth Northsea Swimming Club, Patient, Pharmaceutical industry, Nursing, Drug discovery

SEFA-6179 is a novel, oral, fully synthetic medium chain fatty acid analog for the treatment of IFALD.

Key Points: 
  • SEFA-6179 is a novel, oral, fully synthetic medium chain fatty acid analog for the treatment of IFALD.
  • IFALD, also known as Parental Nutrition-Associated Liver Disease (PNALD), is an orphan liver disease which is a frequent consequence of total parenteral nutrition, or TPN, a life-saving therapy for individuals with intestinal failure caused by insufficient bowel-length or function.
  • The granting of RPD designation for SEFA-6179 underscores the critical need for novel therapies to address IFALD in the pediatric population.
  • This program is intended to encourage the development of new drugs and biologics for the treatment of rare pediatric diseases.

Heidelberg Materials to acquire The SEFA Group, Inc.

Retrieved on: 
Monday, April 24, 2023
Building material, Culture, Recycling, History, Carbon, Plant, Acquisition, SEFA, Heidelberg, Transport, Environment, Bright Star Technology, Management

Heidelberg Materials announced today that is has entered into a definitive purchase agreement to acquire The SEFA Group Inc., the largest recycler of harvested fly ash sold for use in concrete products in the United States.

Key Points: 
  • Heidelberg Materials announced today that is has entered into a definitive purchase agreement to acquire The SEFA Group Inc., the largest recycler of harvested fly ash sold for use in concrete products in the United States.
  • The SEFA Group currently supplies quality fly ash to more than 800 concrete plants in 13 states.
  • “The acquisition of The SEFA Group will further strengthen our cementitious footprint in the fast-growing Southeastern U.S. market,” said Chris Ward, President and CEO of Heidelberg Materials North America.
  • “Our company’s focus on sustainability, customer service, and a technology-driven approach to running our businesses make The SEFA Group a great addition to the Heidelberg Materials operations in North America,” said Gregg Hendrix, CEO of The SEFA Group.

NorthSea Therapeutics Provides Clinical Update Reflecting Progress Across NASH And Metabolic Disorders Programmes

Retrieved on: 
Thursday, January 5, 2023
Biotechnology, Vitamins, Supplements, Health, Pharmaceutical, Clinical Trials, Apolipoprotein, Fibrosis, Short bowel syndrome, CSO, NST, Organic acid, Radio Northsea International, Fatty liver disease, Parenteral nutrition, Phase II, LDL, ICONA, Apolipoprotein B, NASH, Biomarker, Patient, Liver injury, SEFA, Hypertriglyceridemia, Diabetes, Pharmaceutical industry

NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today provides an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic disorders.

Key Points: 
  • NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today provides an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic disorders.
  • NST’s lead product, icosabutate, is a once-daily, oral SEFA currently in a Phase 2b clinical trial (ICONA) for the treatment of non-alcoholic steatohepatitis, or NASH.
  • The study’s primary endpoint is resolution of NASH without worsening of fibrosis, based on changes in liver biopsy parameters compared to baseline after 52 weeks.
  • Icosabutate was also well-tolerated, with no serious safety signals to date, a key attribute for patients with NASH, who require chronic therapy.

Customer Communications Management Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Wednesday, December 21, 2022
Papyrus, Pew, Public, Organization, App Store (iOS/iPadOS), Smart Communications, Social media, Travel, Communication, E-commerce, OpenText, Health, Growth, SMS, COVID-19, Marketing, BFSI, CCM, City centre, Pew Research Center, Automation, Government, Pitney Bowes, Papyrus (software), SEFA, Artificial intelligence, Software as a service, Geography, Adobe, Documentation, Acquisition, Machine learning, Online shopping, Mobile phone, Quadient, Oracle

The customer communications management market is expected to reach $2.20 billion in 2026 at a compound annual growth rate (CAGR) of 12.82%.

Key Points: 
  • The customer communications management market is expected to reach $2.20 billion in 2026 at a compound annual growth rate (CAGR) of 12.82%.
  • The customer communication management is used to facilitate customer interactions and improve sharing, storage, and retrieval of customer communications using various tools and processes.
  • The regions covered in the customer communications management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The customer communication management market research report is one of a series of new reports that provides customer communication management market statistics, including customer communication management industry global market size, regional shares, competitors with a customer communication management market share, detailed customer communication management market segments, market trends and opportunities, and any further data you may need to thrive in the customer communication management industry.

HMS releases a significant new release to the TimeControl multi-function timesheet system. TimeControl 8.3 includes many new and enhanced features

Retrieved on: 
Wednesday, June 15, 2022
Online, Time, Progress Rail, HMS, Government of Quebec, Software, Workplace, Volvo, EXFO, Kelly Services, SEFA, AMD, Severe cognitive impairment, Interpol, NVDA, Foster Wheeler, Maintenance, CAE, Library technical services, Multimedia, Service, Organization, Video game, Online shopping, Cloud

This latest version of TimeControl includes new and enhanced features for TimeControl, the on-premise version of TimeControl, TimeControl Online, the TimeControl Software as a Service subscription, TimeControl Project, the premium version of TimeControl Online as well as TimeControl Industrial and TimeControl Industrial Online.

Key Points: 
  • This latest version of TimeControl includes new and enhanced features for TimeControl, the on-premise version of TimeControl, TimeControl Online, the TimeControl Software as a Service subscription, TimeControl Project, the premium version of TimeControl Online as well as TimeControl Industrial and TimeControl Industrial Online.
  • TimeControl 8.3 Online will be upgraded automatically for TimeControl Online, TimeControl Industrial Online and TimeControl Project subscription clients in the coming weeks.
  • TimeControl Project is a premium version of the TimeControl Online and TimeControl Industrial Online subscription service in the cloud.
  • For more information about TimeControl, TimeControl Industrial and TimeControl Project, monitor the TimeControl blog at blog.timecontrol.com , or the main TimeControl website at www.timecontrol.com.

HMS Software Releases TimeControl Project, an Evolutionary New Product for Project Management at all Levels

Retrieved on: 
Wednesday, April 13, 2022
Online, CAE, Time, Kelly Services, Government of Quebec, View, Timesheet, EXFO, Software, AMD, Organization, SEFA, Premium, Volvo, Military, Library technical services, Progress Rail, 625th Strategic Operations Squadron, Industry, Multimedia, Strategy, Lego Star Wars: The Complete Saga, Capital punishment, Operational level of war, Management, Video game, Online shopping, Cloud

MONTREAL, April 13, 2022 /PRNewswire/ - HMS Software, a thought leader in enterprise project management and enterprise timesheet system has just announced TimeControl Project.

Key Points: 
  • MONTREAL, April 13, 2022 /PRNewswire/ - HMS Software, a thought leader in enterprise project management and enterprise timesheet system has just announced TimeControl Project.
  • TimeControl Project is a completely new approach to project management and brings project planning and project execution tools to an already robust set of functionality in TimeControl.
  • "With TimeControl Project, we have taken a radical new approach to project management systems," explains Chris Vandersluis, President of HMS Software.
  • TimeControl Project is being offered as a premium version of HMS Software's subscription as a service Timesheet, TimeControl Online and TimeControl Industrial Online.

NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease

Retrieved on: 
Wednesday, February 2, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, NSV, Safety, Short bowel syndrome, Patient, Therapy, Cirrhosis, Liver disease, Cell, Lists of diseases, Dyslipidemia, ICONA, PN, Liver, NASH, Steatosis, MCFA, Seed, Liver failure, Hypertriglyceridemia, Cholestasis, Pharmacotherapy, Population, Death, Pharmacokinetics, Rigshospitalet, Adult, Live at Montreux and Northsea, Parenteral nutrition, Fibrosis, Biomarker, Myofibroblast, BASF, Institute of Liver and Biliary Sciences, Department, SEFA, NST, Collagen, BGV, Mouse, Fatty liver disease, Liver injury, United Kingdom, Metabolism, Pharmaceutical industry, Medical imaging, Dietary supplement, Intestinal failure-associated liver disease (IFALD), SEFA-6179, NorthSea Therapeutics, INTESTINAL FAILURE-ASSOCIATED LIVER DISEASE (IFALD), SEFA-6179, NORTHSEA THERAPEUTICS

The Phase 1 SEFA-6179 clinical trial is being conducted in the United Kingdom and is expected to enroll approximately 90 healthy participants.

Key Points: 
  • The Phase 1 SEFA-6179 clinical trial is being conducted in the United Kingdom and is expected to enroll approximately 90 healthy participants.
  • The study is a randomized, placebo-controlled, single and multiple ascending dose trial, evaluating the safety, tolerability and pharmacokinetics of SEFA-6179.
  • The icosabutate Phase 2b ICONA trial in patients with biopsy-confirmed NASH is scheduled to readout in the first quarter of 2023.
  • Two additional SEFAs are in clinical development: SEFA-1024 is in Phase 1 to be developed for patients with severe hypertriglyceridemia, and SEFA-6179 is in Phase 1 development for the orphan indication IFALD (Intestinal Failure Associated Liver Disease).

HMS Software and Processor Powerhouse AMD Collaborate on TimeControl Timesheet System Case Study

Retrieved on: 
Wednesday, January 19, 2022
Online, Progress Rail, SEFA, EXFO, AMD, CAE, Workplace, Software, Time, Kelly Services, HMS, Agreement Respecting a New Relationship Between the Cree Nation and the Government of Quebec, Multimedia, Volvo, Cryptocurrency, Video game console, Video game, Cloud

HMS Software, a leader in timesheet systems has announced a case study of the implementation of its TimeControl timesheet system at AMD.

Key Points: 
  • HMS Software, a leader in timesheet systems has announced a case study of the implementation of its TimeControl timesheet system at AMD.
  • "We've collaborated with AMD on this story over the last few months," explains Chris Vandersluis, President of HMS Software.
  • The case study follows the implementation of the TimeControl Online software as a service to AMD's global engineering team and how AMD has been able to leverage the integration features and real-time data display of the timesheet system.
  • For more information about TimeControl and TimeControl Industrial, monitor the TimeControl blog at blog.timecontrol.com , the TimeControl Industrial website at industrial.timecontrol.com or the main TimeControl website at www.timecontrol.com.

Icosabutate Latest Phase 2b Interim Data Show Significant Decreases in NASH and Fibrosis Biomarkers Independent of Fibrosis Stage and Disease Severity

Retrieved on: 
Tuesday, November 16, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Histology, Population, Biomarker, Hepatitis, NST, Non-alcoholic fatty liver disease, Therapy, Cirrhosis, BGV, Diabetes, Liver, Inflammation, Seed, NAFLD, Lists of diseases, HIV disease progression rates, Association, ICONA, ALT, SEFA, Dyslipidemia, Portsmouth Northsea Swimming Club, NASH, NSV, Membrane protein, FFAR4, Sofinnova, Abstract, Liver transplantation, Hypertriglyceridemia, Fibrosis, Adult, Patient, Squamous cell carcinoma, Chronic liver disease, Liver failure, Obesity, Pharmaceutical industry, Dietary supplement, NASH, Icosabutate, NorthSea Therapeutics, NASH, ICOSABUTATE, NORTHSEA THERAPEUTICS

Rob de Ree, Chief Executive Officer at Northsea added, Northsea is committed to developing novel therapies for patients with life-threatening liver diseases.

Key Points: 
  • Rob de Ree, Chief Executive Officer at Northsea added, Northsea is committed to developing novel therapies for patients with life-threatening liver diseases.
  • Title: Icosabutate, a novel oral free fatty acid 4 (FFAR4) agonist, significantly decreases biomarkers of NASH and fibrosis independent of disease severity (Abstract #1915)
    The presentations will also be made available on the Northsea Therapeutics website ( www.northseatherapeutics.com/publications ) after the data has been presented at the meeting.
  • NASH is a chronic liver disease characterized by liver inflammation and fibrosis and represents a more advanced stage of non-alcoholic fatty liver disease (NAFLD).
  • The icosabutate phase 2b ICONA NASH trial is scheduled to readout in the first quarter of 2023.

HMS releases TimeControl 8.2, a multi-function timesheet update with significant new and enhanced features

Retrieved on: 
Tuesday, November 9, 2021
Online, Software, Maintenance, Android, IOS, Primavera, HMS, Progress Rail, Foster Wheeler, Kelly Services, Interpol, Multimedia, AMD, Government of Quebec, SEFA, Environment, CAE, Workplace, Volvo, Oracle, EXFO, Stan Vandersluys, Time, Video game, Online shopping

HMS Software, a global leader in timesheet systems since the first commercial release of its TimeControl system in 1994 has just released TimeControl 8.2, an update to the TimeControl family of versions with significant new and enhanced functionality.

Key Points: 
  • HMS Software, a global leader in timesheet systems since the first commercial release of its TimeControl system in 1994 has just released TimeControl 8.2, an update to the TimeControl family of versions with significant new and enhanced functionality.
  • In that kind of world, the flexibility of our TimeControl timesheet system has been particularly important."
  • With the releases of TimeControl 8.2, HMS expands on the vision of a multi-purpose, highly adaptive timesheet environment first started with the release of TimeControl in 1994.
  • For more information about TimeControl and TimeControl Industrial, monitor the TimeControl blog at blog.timecontrol.com , the TimeControl Industrial website at industrial.timecontrol.com or the main TimeControl website at www.timecontrol.com.